Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

By Pharmaceutical Processing | October 12, 2010

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the expansion of their research, development and
license agreement for the discovery of novel kinase inhibitors in the field
of oncology. This expanded agreement establishes a third therapeutic target,
with an option for a fourth, in the field of oncology, and it includes a
two-year extension based on the application of the proprietary ArQule Kinase
Inhibitor Platform (AKIP(TM)) technology.

“This technology has provided us with a unique and innovative
approach for discovery in the treatment of cancer,” said Dr. Hideyuki
Haruyama, the Global Head of Research, Daiichi Sankyo. “We expect that the
expansion of this collaboration will produce other drug candidates and lay
the foundation for future growth in this field.”

Consistent with the existing AKIP collaboration, the economic
terms provided for in the expanded agreement include payments for research
support, licensing fees for compounds discovered as a result of this
research, milestone payments related to clinical development, regulatory
review and sales, and tiered royalty payments on net sales of each product.
Daiichi Sankyo will have an option to license compounds directed to the
targets defined under the agreement following the completion of certain
pre-clinical studies. ArQule retains the option to co-commercialize any
resulting licensed products in the U.S.

“Our initial drug discovery collaboration has identified a
development candidate for one target, and we are optimizing advanced lead
compounds for the other target,” said Dr. Thomas C.K. Chan, chief scientific
officer of ArQule. “The expansion of this collaboration will continue to
deploy AKIP technology to discover inhibitors with novel modes of action for
additional oncology targets over the next two years.”

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE